NASDAQ: BTCYBiotricity Inc Stock
$2.14+0.03 (+1.42%)
Updated Sep 29, 2023
BTCY Price
$2.14
Fair Value Price
$2.15
Market Cap
$17.81M
52 Week Low
$1.90
52 Week High
$9.18
P/E
-1.03x
P/B
-0.76x
P/S
3.16x
PEG
N/A
Dividend Yield
N/A
Revenue
$10.60M
Earnings
-$17.29M
Gross Margin
57.8%
Operating Margin
-139.53%
Profit Margin
-170.8%
Debt to Equity
-1.26
Operating Cash Flow
-$11M
Beta
0.64
Next Earnings
Nov 13, 2023
Ex-Dividend
N/A
Next Dividend
N/A
BTCY Overview
Biotricity, Inc., a medical technology company, provides biometric data monitoring solutions primarily in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It offers Bioflux mobile cardiac telemetry solution, an integrated ECG device; and ECG analysis software that analyzes and synthesizes patient ECG monitoring data, as well as software components. The company is based in Redwood City, California.
Zen Score
–
Industry Average (29)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how BTCY scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BTCY ($2.14) is undervalued by 0.51% relative to our estimate of its Fair Value price of $2.15 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
BTCY ($2.14) is not significantly undervalued (0.51%) relative to our estimate of its Fair Value price of $2.15 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
BTCY is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more BTCY due diligence checks available for Premium users.
Be the first to know about important BTCY news, forecast changes, insider trades & much more!
BTCY News
Valuation
BTCY fair value
Fair Value of BTCY stock based on Discounted Cash Flow (DCF)
Price
$2.14
Fair Value
$2.15
Undervalued by
0.51%
BTCY ($2.14) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
BTCY ($2.14) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
BTCY is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
BTCY price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.03x
Industry
48.82x
Market
12.37x
BTCY price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-0.76x
Industry
3.49x
BTCY's financial health
Profit margin
Revenue
$3.0M
Net Income
-$3.4M
Profit Margin
-119.2%
BTCY's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
BTCY's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$6.1M
Liabilities
$29.6M
Debt to equity
-1.26
BTCY's short-term liabilities ($15.10M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BTCY's long-term liabilities ($14.46M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BTCY's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
BTCY's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.8M
Investing
$0.0
Financing
$1.3M
BTCY's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
BTCY vs Medical Device Stocks
Biotricity Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.